---
title: "Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688062.SH.md"
symbol: "688062.SH"
name: "Mabwell (Shanghai) Bioscience Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-19T21:32:35.939Z"
locales:
  - [en](https://longbridge.com/en/quote/688062.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688062.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688062.SH.md)
---

# Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH)

## Company Overview

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provides oncology products, including 9MW2821, a Nectin-4 targeting drug candidate in the Phase III clinical trials for the treatment of cervical cancer; 7MW3711, a B7-H3 targeting ADC for the treatment of advanced malignant solid tumors; and 7MW4911, an ADC that targets CDH17. In addition, the company offers immunology products comprising 9MW1911, an anti-ST2 antibody that is in Phase I clinical trial for the treatment of COPD, and 9MW3811, an anti-IL-11 antibody that is in Phase I clinical trial.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.mabwell.com](https://www.mabwell.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:10.000Z

**Overall: C (0.60)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 32 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 321.05% |  |
| Net Profit YoY | 18.62% |  |
| P/B Ratio | 139.69 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 14906540619.00 |  |
| Revenue | 744612599.82 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -132.89% | E |
| Profit Margin | -123.38% | E |
| Gross Margin | 76.15% | A |
| Revenue YoY | 321.05% | A |
| Net Profit YoY | 18.62% | B |
| Total Assets YoY | 8.99% | B |
| Net Assets YoY | -77.11% | E |
| Cash Flow Margin | 33.47% | D |
| OCF YoY | 321.05% | A |
| Turnover | 0.17 | D |
| Gearing Ratio | 93.67% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Mabwell (Shanghai) Bioscience Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "321.05%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "18.62%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "139.69",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "14906540619.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "744612599.82",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-132.89%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-123.38%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "76.15%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "321.05%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "18.62%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.99%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-77.11%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "33.47%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "321.05%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.17",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "93.67%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -16.23 | 52/81 | - | - | - |
| PB | 139.69 | 82/81 | 24.73 | 20.80 | 10.80 |
| PS (TTM) | 20.02 | 68/81 | 82.76 | 28.09 | 22.91 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-27T16:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 67% |
| Overweight | 1 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 33.40 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688062.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688062.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688062.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/688062.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**